Clinical trial · Interventional
SBRT for Liver Tumors, Liver Metastases, and Pancreatic Tumors
SBRT of Liver Tumors and Metastases and Pancreatic Tumors
NCT07407257CI-TRIAL-00103586completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective observational study evaluates the safety and effectiveness of stereotactic body radiotherapy (SBRT) for liver tumors, liver metastases, and pancreatic tumors. The study focuses on systematic monitoring and optimization of the SBRT treatment process, including adherence to the implemented protocol, with the aim of simplifying methods while maintaining treatment safety.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Metastases | Hepatocellular Carcinoma | PROBABILISTIC | 0.70 |
| Liver Neoplasms | Liver Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Pancreatic Neoplasms | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Stereotactic Body Radiotherapy (SBRT) | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- SBRT Treatment
- description
- Patients with liver tumors, liver metastases, or pancreatic tumors treated with stereotactic body radiotherapy (SBRT) according to the institutional protocol.
- interventionNames
- Radiation: Stereotactic Body Radiotherapy (SBRT)
Primary outcomes (1)
- measure
- Treatment Safety (Radiotherapy-Related Toxicity)
- timeFrame
- From start of SBRT up to 12 months after treatment
- description
- Assessment of acute and late treatment-related toxicity after stereotactic body radiotherapy (SBRT) for liver tumors, liver metastases, and pancreatic tumors, evaluated according to standard toxicity criteria.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Patients with liver tumors, liver metastases, or pancreatic tumors eligible for stereotactic body radiotherapy (SBRT) * Planned treatment with SBRT according to institutional protocol * Ability to comply with treatment and follow-up procedures * Signed informed consent Exclusion Criteria: * Contraindications for SBRT according to institutional radiotherapy protocol * Prior radiotherapy that prevents safe SBRT delivery to the target region * Severe uncontrolled comorbidities preventing safe SBRT treatment * Pregnancy * Inability to provide informed consent or comply with study procedures
References
Publications (0)
Data not yet available
No reference posted for this study.